Cargando…
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047329/ https://www.ncbi.nlm.nih.gov/pubmed/36980184 http://dx.doi.org/10.3390/cells12060843 |
_version_ | 1785013893848891392 |
---|---|
author | Martínez-Bosch, Neus Vilariño, Noelia Alameda, Francesc Mojal, Sergi Arumí-Uria, Montserrat Carrato, Cristina Aldecoa, Iban Ribalta, Teresa Vidal, Noemí Bellosillo, Beatriz Menéndez, Silvia Del Barco, Sonia Gallego, Oscar Pineda, Estela López-Martos, Raquel Hernández, Ainhoa Mesia, Carlos Esteve-Codina, Anna de la Iglesia, Nuria Balañá, Carme Martínez-García, María Navarro, Pilar |
author_facet | Martínez-Bosch, Neus Vilariño, Noelia Alameda, Francesc Mojal, Sergi Arumí-Uria, Montserrat Carrato, Cristina Aldecoa, Iban Ribalta, Teresa Vidal, Noemí Bellosillo, Beatriz Menéndez, Silvia Del Barco, Sonia Gallego, Oscar Pineda, Estela López-Martos, Raquel Hernández, Ainhoa Mesia, Carlos Esteve-Codina, Anna de la Iglesia, Nuria Balañá, Carme Martínez-García, María Navarro, Pilar |
author_sort | Martínez-Bosch, Neus |
collection | PubMed |
description | Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM. |
format | Online Article Text |
id | pubmed-10047329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100473292023-03-29 Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker Martínez-Bosch, Neus Vilariño, Noelia Alameda, Francesc Mojal, Sergi Arumí-Uria, Montserrat Carrato, Cristina Aldecoa, Iban Ribalta, Teresa Vidal, Noemí Bellosillo, Beatriz Menéndez, Silvia Del Barco, Sonia Gallego, Oscar Pineda, Estela López-Martos, Raquel Hernández, Ainhoa Mesia, Carlos Esteve-Codina, Anna de la Iglesia, Nuria Balañá, Carme Martínez-García, María Navarro, Pilar Cells Article Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM. MDPI 2023-03-08 /pmc/articles/PMC10047329/ /pubmed/36980184 http://dx.doi.org/10.3390/cells12060843 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Martínez-Bosch, Neus Vilariño, Noelia Alameda, Francesc Mojal, Sergi Arumí-Uria, Montserrat Carrato, Cristina Aldecoa, Iban Ribalta, Teresa Vidal, Noemí Bellosillo, Beatriz Menéndez, Silvia Del Barco, Sonia Gallego, Oscar Pineda, Estela López-Martos, Raquel Hernández, Ainhoa Mesia, Carlos Esteve-Codina, Anna de la Iglesia, Nuria Balañá, Carme Martínez-García, María Navarro, Pilar Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker |
title | Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker |
title_full | Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker |
title_fullStr | Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker |
title_full_unstemmed | Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker |
title_short | Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker |
title_sort | gal-1 expression analysis in the gliocat multicenter study: role as a prognostic factor and an immune-suppressive biomarker |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047329/ https://www.ncbi.nlm.nih.gov/pubmed/36980184 http://dx.doi.org/10.3390/cells12060843 |
work_keys_str_mv | AT martinezboschneus gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT vilarinonoelia gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT alamedafrancesc gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT mojalsergi gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT arumiuriamontserrat gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT carratocristina gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT aldecoaiban gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT ribaltateresa gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT vidalnoemi gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT bellosillobeatriz gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT menendezsilvia gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT delbarcosonia gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT gallegooscar gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT pinedaestela gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT lopezmartosraquel gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT hernandezainhoa gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT mesiacarlos gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT estevecodinaanna gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT delaiglesianuria gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT balanacarme gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT martinezgarciamaria gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker AT navarropilar gal1expressionanalysisinthegliocatmulticenterstudyroleasaprognosticfactorandanimmunesuppressivebiomarker |